Wall Street Zen Upgrades Glaukos (NYSE:GKOS) to “Buy”

by · The Cerbat Gem

Glaukos (NYSE:GKOS – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

A number of other research firms have also issued reports on GKOS. Piper Sandler reissued an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a research report on Wednesday, January 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. Needham & Company LLC reissued a “buy” rating and set a $125.00 target price on shares of Glaukos in a research note on Wednesday, January 14th. Citigroup boosted their price target on shares of Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Stifel Nicolaus increased their price objective on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $132.54.

Get Our Latest Stock Analysis on GKOS

Glaukos Stock Down 0.9%

Shares of Glaukos stock opened at $112.54 on Friday. Glaukos has a 1 year low of $73.16 and a 1 year high of $161.78. The company has a market cap of $6.46 billion, a P/E ratio of -73.08 and a beta of 0.70. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average price of $114.34 and a 200 day moving average price of $97.47.

Insider Buying and Selling at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 315 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total transaction of $33,075.00. Following the transaction, the chief financial officer directly owned 50,488 shares in the company, valued at $5,301,240. This trade represents a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Marc Stapley sold 15,000 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total value of $1,915,650.00. Following the completion of the sale, the director directly owned 37,449 shares of the company’s stock, valued at $4,782,611.79. This represents a 28.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 329,655 shares of company stock worth $37,752,234 in the last ninety days. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Larson Financial Group LLC boosted its position in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Glaukos by 16.2% in the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 136 shares during the last quarter. CWM LLC boosted its holdings in shares of Glaukos by 25.2% during the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 143 shares during the period. Evergreen Capital Management LLC boosted its holdings in shares of Glaukos by 4.3% during the 4th quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 145 shares during the period. Finally, Crossmark Global Holdings Inc. grew its stake in Glaukos by 3.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 4,034 shares of the medical instruments supplier’s stock valued at $455,000 after buying an additional 145 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

About Glaukos

(Get Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

Read More